China Universal Asset Management Co. Ltd. Purchases 23,138 Shares of Sanofi (NASDAQ:SNY)

China Universal Asset Management Co. Ltd. lifted its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 69.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,230 shares of the company's stock after acquiring an additional 23,138 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Sanofi were worth $3,241,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. POM Investment Strategies LLC bought a new position in shares of Sanofi in the 2nd quarter valued at about $25,000. Larson Financial Group LLC boosted its holdings in shares of Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company's stock worth $29,000 after buying an additional 500 shares during the period. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi in the third quarter valued at approximately $29,000. Palisade Asset Management LLC bought a new stake in Sanofi in the 1st quarter valued at $31,000. Finally, Concord Wealth Partners increased its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after buying an additional 363 shares during the period. 10.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on SNY shares. Argus increased their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, July 26th. Citigroup raised Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Finally, StockNews.com cut Sanofi from a "strong-buy" rating to a "buy" rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Price Performance

SNY traded down $0.53 during trading on Tuesday, hitting $53.83. 1,934,077 shares of the stock traded hands, compared to its average volume of 2,039,439. The business has a 50 day moving average price of $56.08 and a 200 day moving average price of $51.84. The company has a market cap of $136.61 billion, a price-to-earnings ratio of 27.46, a PEG ratio of 1.55 and a beta of 0.60. Sanofi has a twelve month low of $44.05 and a twelve month high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. Sanofi's revenue was up 12.3% compared to the same quarter last year. During the same period last year, the firm posted $2.55 earnings per share. Equities research analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.